ZUPLENZ for radiotherapy-induced nausea and vomiting (RINV)


RINV occurs in up to 80% of patients undergoing radiotherapy17



  • Studies suggest that RINV may be undertreated
    — In a large prospective observational study (n=914), only 14% of patients undergoing radiotherapy received antiemetic treatment—and then more often as a rescue measure18
    — In another study (N=368), one-third of patients with RINV would have preferred additional antiemetic treatment19

In radiotherapy1,8



  • 61% of patients receiving fractionated radiotherapy did not experience emesis, need rescue antiemetic therapy, or withdraw from the study1,8
  • Significantly greater efficacy in achieving zero emetic episodes in radiotherapy-induced nausea and vomiting vs prochlorperazine1,8
  • 5-HT3 receptor antagonists are recommended by major guidelines for management of RINV10-13

ASCO | NCCN | MASCC | ASHP

Important Safety Information

  • In clinical studies of use in radiotherapy, the most frequently reported adverse events were headache, constipation, and diarrhea, which were similar to those reported by patients receiving ondansetron and concurrent chemotherapy

ZUPLENZ delivers the trusted efficacy of ondansetron in a quick-dissolving film

  • Can be dosed prior to therapy1
  • Easy to take for patients who have trouble swallowing tablets or who refuse suppositories

ASCO=American Society of Clinical Oncology.
NCCN=National Comprehensive Cancer Network.
MASCC=Multinational Association of Supportive Care in Cancer.
ASHP=American Society of Health-System Pharmacists.


*Not an actual patient.


For the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting.

The concomitant use of apomorphine with ondansetron is contraindicated based upon reports of profound hypotension and loss of consciousness.

Patients known to have hypersensitivity to ondansetron and to other selective 5-HT3 receptor antagonists should not take ZUPLENZ. Hypersensitivity reactions, including anaphylaxis and bronchospasm, have been reported. Rarely and predominantly with intravenous ondansetron, transient electrocardiographic changes, including QT interval prolongation, have occurred.

The use of ZUPLENZ in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask a progressive ileus and/or gastric distension. ZUPLENZ does not stimulate gastric or intestinal peristalsis and should not be used instead of nasogastric suction.

The most common adverse drug reactions (≥5%) reported in clinical trials of patients receiving ondansetron for prevention of nausea and vomiting associated with cancer chemotherapy or radiotherapy were headache, malaise/fatigue, constipation, and diarrhea. For postoperative nausea and vomiting, headache occurred at a rate significantly different from placebo.

ZUPLENZ is available by prescription only. Please click here for complete Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch, or call 1-800-FDA-1088.

For more information about ZUPLENZ, call 1-866-662-7199